Urolithin A (Mitopure): real trials, modest results

Urolithin A is the rare longevity supplement with a genuine clinical evidence base — and a genuine lesson in reading that evidence carefully. Almost everything written about it leads with “clinically proven to build muscle.” The trials are real; what they actually found is more nuanced, and the nuance is the point.

What it is and how it works

Urolithin A isn’t something you eat directly — it’s a postbiotic: your gut bacteria make it from ellagitannins (compounds in pomegranates, walnuts and berries), and many people’s microbiomes don’t produce much, which is the rationale for supplementing the finished metabolite (branded Mitopure). Its mechanism is mitophagy — the cellular housekeeping that identifies and clears damaged mitochondria so healthier ones can take over. In worms and rodents, urolithin A induced mitophagy, improved muscle function and extended lifespan.^[1] That preclinical signal is what launched the human program.

The human evidence: real randomized trials

Unusually for a supplement, urolithin A has been through proper trials. A first-in-humanstudy in sedentary elderly adults established that it is safe and bioavailable, and that 4 weeks of 500–1,000 mg shifted skeletal-muscle mitochondrial gene expression toward a healthier signature.^[2] Two placebo-controlled RCTs followed, and this is where the careful reading starts.

Read the endpoints carefully

Here is the part the marketing flattens. In the middle-aged trial, the widely-quoted ~12% strength improvement was a secondary outcome — the pre-specified primary endpoint (peak power output) was not significantly improved.^[3] In the older-adult trial (n=66), urolithin A significantly improved muscle endurance and lowered inflammatory and mitochondrial plasma biomarkers, but both primary endpoints — the 6-minute walk distance and maximal muscle ATP production — missed significance.^[4] The honest pattern across the program: urolithin A reproducibly improves endurance and biomarkers, while its effect on raw strength, power and walking is modest and inconsistent.

Safety

On safety the picture is clean: across the trials, doses up to 1,000 mg per day for up to four months were safe and well tolerated, with no significant excess of adverse events versus placebo.^[2][4] That favorable safety profile is part of why urolithin A is one of the more defensible supplements to consider — the question is efficacy, not safety.

The honest bottom line

Urolithin A is a legitimately interesting compound: a real mitophagy inducer with a first-in-human safety trial and multiple placebo-controlled RCTs — a tier of evidence most supplements never reach.^[2] But the trials are also a model of why endpoints matter: the durable, replicated wins are in muscle endurance and mitochondrial biomarkers, while the headline strength and power claims rest on secondary outcomes in trials whose primary endpoints missed. Treat it as a well-tolerated supplement with modest, real endurance/mitochondrial benefits — not a proven strength builder. For the broader cellular-energy story, see our NAD+ precursors monograph; for other longevity compounds graded the same honest way, spermidine and fisetin.